ACE2 and Hypertension: However, ACE2 as a potential therapeutic target in hypertension has been disappointing because ACE2 inhibitors do not increase blood pressure significantly in experimental models and agents that enhance ACE2 activity, including recombinant human ACE2 (rhACE2), have failed to consistently reduce blood pressure in hypertensive models and humans [28,48].